




# Pulse Survey: GLP-1 Drugs


This survey, conducted from January 21, 2024 to February 1, 2024, captures Canadian employers' coverage and considerations surrounding GLP-1 drugs, which have historically been prescribed for diabetes and weight loss. It also provides a snapshot of other approaches used by employers that offer health care coverage to address certain chronic health conditions. The data reflects responses from Canadian corporate plan sponsors, professional service providers and multi-employer plans.

## Coverage of GLP-1 Drugs (n=82)




## Considering Offering Coverage for GLP-1 Drugs for Weight Loss\* (n=54)


\* Respondents who only offer GLP-1 drugs for diabetes answered this question.



## Extended Group Health Plan Funding (n=79)




## Services Covered Under Your Extended Group Health Plan for Diabetes or Weight Loss\* (n=82)



\* Respondents were asked to select all that apply.

The following are results from organizations that offer GLP-1 drugs for weight loss.


**Top Ten Factors When Considering GLP-1 Coverage for Obesity Care\*** (n=15\*\*)



\* Respondents were asked to select all that apply.

\*\*Due to small number of responses, please use caution when generalizing findings to a particular population.

**Cost-Control Mechanisms in Place for GLP-1 Drugs for Weight Loss\*** (n=15\*\*)



\* Respondents were asked to select all that apply.

\*\*Due to small number of responses, please use caution when generalizing findings to a particular population.

**Representation of GLP-1 Drugs for Weight Loss in Total Annual Claims for 2023**

Response rates were too low to report percentage of claims costs.